In Vivo Inhibitory Effects of Destruxin B on Human Colorectal Cancer

• Main Authors: Wan-chun Liao, 廖婉君
• Other Authors: Chi-Chiang Yang
• Format: Others
• Language: en_US
• Published: 2010
• Online Access: http://ndltd.ncl.edu.tw/handle/11304542819274754242

碩士 === 朝陽科技大學 === 生化科技研究所碩士班 === 98 === Colon carcinoma is one of the most common malignant diseases worldwide. Previous studies reported destruxins B, one of the secondary metabolites of Metarhiziu anisopliae has potent growth suppression effect on human HT-29 adenocarcinoma cells. The purpose of this study is to compare, in vitro and in vivo, the anti-colon cancer activities of destruxin B and investigate the in vivo anti-colon cancer pathway of destruxin B. The destruxins were isolated and purified according to the previous report (Chen et al., 1999) and characterized by HPLC, ESI-MASS and 1H NMR spectroscopies. A significant inhibition in cell viability was observed upon treatments with various concentrations of destruxin B and was in a dose-dependent manner. The IC50 of destruxin B at 48 hours was 2μM on HT-29. At the end of the experiment, Destruxin B, at low dose concentration ( 0.6 mg/kg/day) could inhibit tumor growth in a xenograft mice model and the caspase-3 is activated after 2 weeks treatment of destruxin B. In conclusion, destruxin B was suggested potentially to be explored as a new therapeutic agent against human colorectal carcinoma cancer.